SEC Form 4 · accession 0001171843-15-000467
TETRALOGIC PHARMACEUTICALS Corp · TLOG
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
J Kevin Buchi
Officer — President & CEO · Director
Period of report
Jan 28, 2015
Accepted (ET)
Jan 30, 2015 · 2:35 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001361248
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock OptionF1 | $5.25 | Jan 28, 2015 | A | 200,000 | A | — | Jan 28, 2025 | Common Stock | 200,000 | 1,222,389 | D |
| Restricted Stock UnitF2 | — | Jan 28, 2015 | A | 150,000 | A | — | Jan 28, 2018 | Common Stock | 150,000 | 0 | D |
Explanation of responses
- F1Beginning January 28, 2015, stock options will vest and become exercisable at 2% per month until fully vested. Stock options are subject to the reporting person's continued service as of each vesting date.
- F2Each restricted stock unit represents a contingent right to receive one share of TetraLogic Pharmaceuticals Corporation common stock. All 150,000 restricted stock units shall vest on January 28, 2018. Restricted stock units are subject to the reporting person's continued service as of the vesting date.